High Recurrence Rate of Idiopathic Peptic Ulcers in Long-Term Follow-up
2
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Background/Aims: Our aim was to compare the long-term clinical outcomes of idiopathic peptic ulcer disease (IPUD)with those of Helicobacter pylori -positive and nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcer disease (PUD). Methods: Patients with endoscopically diagnosed PUD were retrospectively reviewed. According to their H. pylori-infection status and history of NSAIDs use, patients were categorized into three groups: H. pylori-positive PUD, NSAIDinduced PUD, and IPUD. Clinical outcomes were analyzed,and the recurrence rate of PUD was compared among the three groups. Results: A total of 238 patients were enrolled. Those with IPUD, NSAID-induced PUD, and H. pylori-positive PUD comprised of 56, 60, and 122 patients, respectively. The 5-year cumulative incidences of recurrent ulcers were 24.3% (95% confidence interval [CI], 11.6% to 37.0%) in IPUD, 10.9% (95% CI, 2.6% to 19.2%) in NSAID-induced PUD,and 3.8% (95% CI, 0.1% to 7.5%) in H. pylori -positive PUD (IPUD vs NSAID-induced PUD/H. pylori-positive PUD, p=0.43/p<0.001 by log-rank test). In the Cox-proportional hazards model, only IPUD remained as an independent risk factor associated with recurrent ulcers (hazard ratio, 5.97; 95%CI, 1.94 to 18.34; p=0.002). Conclusions: IPUD exhibited a higher recurrence rate than H. pylori-positive and NSAIDinduced PUD in long-term follow-up and was an independent risk factor for ulcer recurrence.
Abstract
Background/Aims: Our aim was to compare the long-term clinical outcomes of idiopathic peptic ulcer disease (IPUD)with those of Helicobacter pylori -positive and nonsteroidal anti-inflammatory drug (NSAID)-induced peptic ulcer disease (PUD). Methods: Patients with endoscopically diagnosed PUD were retrospectively reviewed. According to their H. pylori-infection status and history of NSAIDs use, patients were categorized into three groups: H. pylori-positive PUD, NSAIDinduced PUD, and IPUD. Clinical outcomes were analyzed,and the recurrence rate of PUD was compared among the three groups. Results: A total of 238 patients were enrolled. Those with IPUD, NSAID-induced PUD, and H. pylori-positive PUD comprised of 56, 60, and 122 patients, respectively. The 5-year cumulative incidences of recurrent ulcers were 24.3% (95% confidence interval [CI], 11.6% to 37.0%) in IPUD, 10.9% (95% CI, 2.6% to 19.2%) in NSAID-induced PUD,and 3.8% (95% CI, 0.1% to 7.5%) in H. pylori -positive PUD (IPUD vs NSAID-induced PUD/H. pylori-positive PUD, p=0.43/p<0.001 by log-rank test). In the Cox-proportional hazards model, only IPUD remained as an independent risk factor associated with recurrent ulcers (hazard ratio, 5.97; 95%CI, 1.94 to 18.34; p=0.002). Conclusions: IPUD exhibited a higher recurrence rate than H. pylori-positive and NSAIDinduced PUD in long-term follow-up and was an independent risk factor for ulcer recurrence.
참고문헌 (29)
- Hopkins RJ, "Relationship between Helicobacter pylori eradication and reduced duodenal and gastric ulcer recurrence: a review", Gastroenterology, 110, pp.1244~1252 (1996)
- Nishikawa K, "Non-Helicobacter pylori and non-NSAID peptic ulcer disease in the Japanese population", Eur J Gastroenterol Hepatol, 12, pp.635~640 (2000)
- Ciociola AA, "Helicobacter pylori infection rates in duodenal ulcer patients in the United States may be lower than previously estimated", Am J Gastroenterol, 94, pp.1834~1840 (1999)
- Jang HJ, "Has peptic ulcer disease changed during the past ten years in Korea? A prospective multi-center study", Dig Dis Sci, 53, pp.1527~1531 (2008)
- Yim JY, "Seroprevalence of Helicobacter pylori in South Korea", Helicobacter, 12, pp.333~340 (2007)
- Hung LC, "Long-term outcome of Helicobacter pylori-negative idiopathic bleeding ulcers: a prospective cohort study", Gastroenterology, 128, pp.1845~1850 (2005)
- Wong GL, "High incidence of mortality and recurrent bleeding in patients with Helicobacter pylori-negative idiopathic bleeding ulcers", Gastroenterology, 137, pp.525~531 (2009)
- Bytzer P, "Helicobacter pylori-negative duodenal ulcers: prevalence, clinical characteristics, and prognosis: results from a randomized trial with 2-year follow-up", Am J Gastroenterol, 96, pp.1409~1416 (2001)
- Tam YH, "Helicobacter pylori-positive versus Helicobacter pylori-negative idiopathic peptic ulcers in children with their long-term outcomes", J Pediatr Gastroenterol Nutr, 48, pp.299~305 (2009)
- Malfertheiner P, "Management of Helicobacter pylori infection: the Maastricht IV", Florence Consensus Report, 2012, pp.61, 646~664
- Huang JQ, "Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis", Lancet, 359, pp.14~22 (2002)
- Xia HH, "Clinical and endoscopic characteristics of non-Helicobacter pylori, non-NSAID duodenal ulcers: a long-term prospective study", Aliment Pharmacol Ther, 15, pp.1875~1882 (2001)
- Leong RW, "Differences in peptic ulcer between the East and the West", Gastroenterol Clin North Am, 38, pp.363~379 (2009)
- Yeomans ND, "Management of peptic ulcer disease not related to Helicobacter", J Gastroenterol Hepatol, 17, pp.488~494 (2002)
- Quan C, "Management of peptic ulcer disease not related to Helicobacter pylori or NSAIDs", Am J Gastroenterol, 97, pp.2950~2961 (2002)
- McColl KE, "How I manage H. pylori-negative, NSAID", aspirin-negative peptic ulcers, 2009, pp.104, 190~193
- Malfertheiner P, "Peptic ulcer disease", Lancet, 374, pp.1449~1461 (2009)
- Gisbert JP, "Review article: Helicobacter pylori-negative duodenal ulcer disease", Aliment Pharmacol Ther, 30, pp.791~815 (2009)
- McColl KE, "A study of the pathogenesis of Helicobacter pylori negative chronic duodenal ulceration", Gut, 34, pp.762~768 (1993)
- Goenka MK, "Helicobacter pylori negative, non-steroidal anti-inflammatory drug-negative peptic ulcers in India", Indian J Gastroenterol, 30, pp.33~37 (2011)
- Verdu EF, "Effect of curing Helicobacter pylori infection on intragastric pH during treatment with omeprazole", Gut, 37, pp.743~748 (1995)
- Gillen D, "Helicobacter pylori infection potentiates the inhibition of gastric acid secretion by omeprazole", Gut, 44, pp.468~475 (1999)
- Howden CW, "Current indications for acid suppressants in Helicobacter pylori-negative ulcer disease", Best Pract Res Clin Gastroenterol, 15, pp.401~412 (2001)
- Chow DK, "Non-NSAID non-H. pylori ulcer disease", Pract Res Clin Gastroenterol, 23, pp.3~9 (2009)
- Miwa H, "Recurrent peptic ulcers in patients following successful Helicobacter pylori eradication: a multicenter study of 4940 patients", Helicobacter, 9, pp.9~16 (2004)
- Lanza FL, "Guidelines for prevention of NSAID-related ulcer complications", Am J Gastroenterol, 104, pp.728~738 (2009)
- McColl KE, "Helicobacter pylori-negative nonsteroidal anti-inflammatory drug-negative ulcer", Gastroenterol Clin North Am, 38, pp.353~361 (2009)
- Roy PK, "Zollinger-Ellison syndrome. Clinical presentation in 261 patients", Medicine (Baltimore), 79, pp.379~411 (2000)
- Isenberg JI, "Zollinger-Ellison syndrome", Gastroenterology, 65, pp.140~165 (1973)